Liang T, Lee C, Lee S, Wu C, Chen K, Hsu P
Arch Rheumatol. 2020; 35(2):170-179.
PMID: 32851365
PMC: 7406163.
DOI: 10.46497/ArchRheumatol.2020.7464.
Nadrian H, Hosseini Niaz Y, Basiri Z, Tahamoli Roudsari A
BMC Rheumatol. 2019; 3:4.
PMID: 31245787
PMC: 6582489.
DOI: 10.1186/s41927-019-0069-4.
Boyadzhieva V, Stoilov N, Ivanova M, Petrova G, Stoilov R
Front Pharmacol. 2018; 9:1303.
PMID: 30524277
PMC: 6256982.
DOI: 10.3389/fphar.2018.01303.
Kumar A, Marwaha V
Med J Armed Forces India. 2016; 59(2):90-2.
PMID: 27407474
PMC: 4923781.
DOI: 10.1016/S0377-1237(03)80045-X.
Bolten W, Reiter S
Z Rheumatol. 2012; 71(9):816-22.
PMID: 23052403
DOI: 10.1007/s00393-012-1026-4.
Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience.
Singh H, Gupta V, Ray S, Kumar H, Talapatra P, Kaur M
Clin Rheumatol. 2012; 31(12):1663-9.
PMID: 22983768
DOI: 10.1007/s10067-012-2070-9.
A systems biology approach to synovial joint lubrication in health, injury, and disease.
Hui A, McCarty W, Masuda K, Firestein G, Sah R
Wiley Interdiscip Rev Syst Biol Med. 2011; 4(1):15-37.
PMID: 21826801
PMC: 3593048.
DOI: 10.1002/wsbm.157.
Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis.
Lovell D, Passo M, Beukelman T, Bowyer S, Gottlieb B, Henrickson M
Arthritis Care Res (Hoboken). 2010; 63(1):10-6.
PMID: 20842714
PMC: 3016458.
DOI: 10.1002/acr.20348.
Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility.
Bakker M, Jacobs J, Verstappen S, Bijlsma J
Ann Rheum Dis. 2007; 66 Suppl 3:iii56-60.
PMID: 17934098
PMC: 2095293.
DOI: 10.1136/ard.2007.078360.
Biological drug use: US perspectives on indications and monitoring.
Cush J
Ann Rheum Dis. 2005; 64 Suppl 4:iv18-23.
PMID: 16239379
PMC: 1766900.
DOI: 10.1136/ard.2005.042549.
DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment.
Vander Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F
Arthritis Res Ther. 2005; 7(5):R1063-71.
PMID: 16207323
PMC: 1257436.
DOI: 10.1186/ar1787.
Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.
Nurmohamed M, Dijkmans B
Drugs. 2005; 65(5):661-94.
PMID: 15748099
DOI: 10.2165/00003495-200565050-00006.
Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis.
Fransen J, Laan R, van der Laar M, Huizinga T, Van Riel P
Ann Rheum Dis. 2004; 63(10):1222-6.
PMID: 15361375
PMC: 1754779.
DOI: 10.1136/ard.2003.018861.
Effective use of TNF antagonists.
Yocum D
Arthritis Res Ther. 2004; 6 Suppl 2:S24-30.
PMID: 15228618
PMC: 2833462.
DOI: 10.1186/ar997.
Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?.
Schwartzman S, Fleischmann R, Morgan Jr G
Arthritis Res Ther. 2004; 6 Suppl 2:S3-S11.
PMID: 15228615
PMC: 2833457.
DOI: 10.1186/ar1013.
Current and new antitumor necrosis factor agents in perspective.
Maini R
Arthritis Res Ther. 2004; 6 Suppl 2:S1-2.
PMID: 15228614
PMC: 2833459.
DOI: 10.1186/ar994.
Patients with rheumatoid arthritis in clinical care.
Smolen J, Aletaha D
Ann Rheum Dis. 2004; 63(3):221-5.
PMID: 14962951
PMC: 1754912.
DOI: 10.1136/ard.2003.012575.
The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care.
Smolen J, Aletaha D
Curr Rheumatol Rep. 2003; 5(5):336-40.
PMID: 12967513
DOI: 10.1007/s11926-003-0014-8.
Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
Culy C, Keating G
Drugs. 2002; 62(17):2493-537.
PMID: 12421111
DOI: 10.2165/00003495-200262170-00013.
